Neovascular Changes after Pegaptanib in Diabetics

Ophthalmology

Volumn 114, Issue 3, 2007, Pages 615-616

  Bansal, A Gaurav ^a   Narayanan, R ^a   Majji, A Babu ^a   Thomas, R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB; VASCULOTROPIN;

CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; HUMAN; LASER COAGULATION; LETTER; NEOVASCULARIZATION (PATHOLOGY); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; HUMANS; RANDOMIZED CONTROLLED TRIALS; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847166866     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.10.009     Document Type: Letter

References (2)

1. Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113 (2006) 23-28
2. Sackett D.L., Haynes R.B., Guyatt G.H., and Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. 2nd ed. (1991), Lippincott Williams & Wilkins, Philadelphia 283-301